NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Tops Revenue Estimates

Core Insights - NewAmsterdam Pharma Company N.V. reported a quarterly loss of $0.15 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.52, representing an earnings surprise of +71.15% [1] - The company achieved revenues of $19.15 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 486.19%, compared to revenues of $2.28 million in the same quarter last year [2] - The stock has underperformed the market, losing about 15.5% since the beginning of the year, while the S&P 500 has gained 7.1% [3] Financial Performance - Over the last four quarters, NewAmsterdam Pharma has surpassed consensus EPS estimates two times and topped consensus revenue estimates four times [2] - The current consensus EPS estimate for the upcoming quarter is -$0.50 on revenues of $3.5 million, and for the current fiscal year, it is -$1.81 on revenues of $13.73 million [7] Market Outlook - The company's earnings outlook will be crucial for future stock performance, with management's commentary on the earnings call expected to influence investor sentiment [3][4] - The Zacks Rank for NewAmsterdam Pharma is currently 4 (Sell), indicating expectations of underperformance in the near future [6] - The Medical - Drugs industry, to which NewAmsterdam belongs, is currently in the top 34% of Zacks industries, suggesting a favorable industry outlook [8]